Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SHR-1905 in chronic rhinosinusitis with nasal polyps
CTR20231612Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1905 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Hengrui Therapeutics. Started Sep 2023; status: completed.
02
Drugs
SHR-1905
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20231612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231612.